CCM
ENTA icon

Consonance Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Consonance Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-570,662
Closed -$20.6M – 23
2015
Q3 		$20.6M Sell
570,662
-670,659
-54% -$28.8M 2.9% 11
2015
Q2 		$55.8M Sell
1,241,321
-311,641
-20% -$12.1M 5.61% 10
2015
Q1 		$47.6M Sell
1,552,962
-143,185
-8% -$5.57M 4.33% 11
2014
Q4 		$86.2M Buy
1,696,147
+97,038
+6% +$4.34M 11.11% 1
2014
Q3 		$63.3M Buy
1,599,109
+53,012
+3% +$2.11M 8.68% 2
2014
Q2 		$66.6M Buy
1,546,097
+291,638
+23% +$11.1M 9.91% 1
2014
Q1 		$50.2M Buy
1,254,459
+403,165
+47% +$14.6M 7.46% 4
2013
Q4 		$23.2M Buy
851,294
+281,801
+49% +$6.83M 3.81% 14
2013
Q3 		$13.1M Buy
+569,493
New +$10.9M 3.26% 16

Other funds holding ENTA

ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Consonance Capital Management's ENTA Position: Q4 2015 in Review

Consonance Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2015, closing a stake of 570,662 shares — an estimated $20.6M sold.

Consonance Capital Management first reported a position in ENTA in Q3 2013 and held it in 9 quarters. The position peaked at $86.2M in Q4 2014. 136 funds tracked by Wall St. Rank hold ENTA as of Q4 2015.

  • Consonance Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Consonance Capital Management sold 570,662 Enanta Pharmaceuticals shares in Q4 2015, an estimated $20.6M.
  • Consonance Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 9 quarters.
  • Consonance Capital Management's Enanta Pharmaceuticals position peaked at $86.2M in Q4 2014.
  • 136 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2015.

Based on Consonance Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.